2020
Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease
Weintraub D, Caspell‐Garcia C, Simuni T, Cho HR, Coffey CS, Aarsland D, Alcalay RN, Barrett MJ, Chahine LM, Eberling J, Espay AJ, Hamilton J, Hawkins KA, Leverenz J, Litvan I, Richard I, Rosenthal LS, Siderowf A, York M, Initiative P. Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease. Annals Of Clinical And Translational Neurology 2020, 7: 449-461. PMID: 32285645, PMCID: PMC7187707, DOI: 10.1002/acn3.51022.Peer-Reviewed Original ResearchConceptsParkinson's disease participantsNeuropsychiatric symptomsParkinson's diseaseHealthy controlsCognitive impairmentMedication useYear 5Anticholinergic medication useCross-sectional prevalenceParkinson's disease patientsHypnotic useDisease patientsNeuropsychiatric featuresDisease onsetAnnual visitsSymptomsDisorder subtypesAbsolute prevalenceDiseaseTime pointsPrevalenceBaselineImpairmentParticipantsOnset
2018
Depression Predicts Delirium After Coronary Artery Bypass Graft Surgery Independent of Cognitive Impairment and Cerebrovascular Disease: An Analysis of the Neuropsychiatric Outcomes After Heart Surgery Study
Oldham MA, Hawkins KA, Lin IH, Deng Y, Hao Q, Scoutt LM, Yuh DD, Lee HB. Depression Predicts Delirium After Coronary Artery Bypass Graft Surgery Independent of Cognitive Impairment and Cerebrovascular Disease: An Analysis of the Neuropsychiatric Outcomes After Heart Surgery Study. American Journal Of Geriatric Psychiatry 2018, 27: 476-486. PMID: 30709616, PMCID: PMC6443412, DOI: 10.1016/j.jagp.2018.12.025.Peer-Reviewed Original ResearchConceptsMiddle cerebral arteryMild cognitive impairmentCerebrovascular diseaseCognitive impairmentRisk factorsCoronary artery bypass graft surgeryStenosis severityProspective observational cohort studyArtery bypass graft surgeryBilateral middle cerebral arteriesTertiary care academic hospitalHeart Surgery studyPreoperative cognitive assessmentUndergoing CABG surgeryBypass graft surgeryConfusion Assessment MethodRisk of deliriumDelirium risk factorsObservational cohort studyPostoperative day 2Clinical Dementia RatingDepression InterviewPreoperative depressionStructured HamiltonStudy psychiatristGuanfacine treatment for prefrontal cognitive dysfunction in older participants: a randomized clinical trial
Barcelos NM, Van Ness PH, Wagner AF, MacAvoy MG, Mecca AP, Anderson GM, Trentalange M, Hawkins KA, Sano M, Arnsten AFT, van Dyck CH. Guanfacine treatment for prefrontal cognitive dysfunction in older participants: a randomized clinical trial. Neurobiology Of Aging 2018, 70: 117-124. PMID: 30007160, PMCID: PMC6503670, DOI: 10.1016/j.neurobiolaging.2018.05.033.Peer-Reviewed Original ResearchConceptsDose of guanfacineQuality of lifeZ-scoreCognitive functionPrefrontal cognitive dysfunctionCommon adverse eventsPrimary outcome measureRandomized clinical trialsGlobal functionOlder participantsHealthy older participantsPrefrontal cognitive functionDry mouthAdverse eventsAgonist guanfacineClinical trialsGuanfacine treatmentCognitive dysfunctionMean changeOutcome measuresPlaceboGuanfacineOlder individualsWeeksDose
2017
Cognition and the course of prodromal Parkinson's disease
Weintraub D, Chahine LM, Hawkins KA, Siderowf A, Eberly S, Oakes D, Seibyl J, Stern MB, Marek K, Jennings D, Investigators T. Cognition and the course of prodromal Parkinson's disease. Movement Disorders 2017, 32: 1640-1645. PMID: 29063713, PMCID: PMC5722226, DOI: 10.1002/mds.27189.Peer-Reviewed Original ResearchConceptsSpeed/attentionCognitive declineProdromal participantsBaseline neuropsychological test performanceExecutive function/Role of cognitionNeuropsychological test performanceFuture cognitive declineBaseline cognitive scoresCognitive domainsGlobal cognitionBaseline cognitionCognitive scoresCognitionTest performanceFuture declinePD-convertersDopamine systemHyposmic individualsProdromal PDLongitudinal changesFunction/ParticipantsDopamine transporter bindingIndividualsMultiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease
Caspell-Garcia C, Simuni T, Tosun-Turgut D, Wu IW, Zhang Y, Nalls M, Singleton A, Shaw LA, Kang JH, Trojanowski JQ, Siderowf A, Coffey C, Lasch S, Aarsland D, Burn D, Chahine LM, Espay AJ, Foster ED, Hawkins KA, Litvan I, Richard I, Weintraub D, Initiative T. Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease. PLOS ONE 2017, 12: e0175674. PMID: 28520803, PMCID: PMC5435130, DOI: 10.1371/journal.pone.0175674.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAmyloid beta-PeptidesBiomarkersBrain-Derived Neurotrophic FactorCatechol O-MethyltransferaseCognitive DysfunctionDiffusion Tensor ImagingDopamine Plasma Membrane Transport ProteinsFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedParkinson DiseasePolymorphism, Single NucleotideTau ProteinsTomography, Emission-Computed, Single-PhotonConceptsParkinson's diseaseCognitive impairmentDe novo Parkinson's diseaseDopamine transporter single-photon emissionLongitudinal mixed-effects modelsNovo Parkinson's diseaseYears of diseaseIdiopathic Parkinson's diseaseMovement Disorders CenterSingle nucleotide polymorphismsStructural magnetic resonance imagingClinical trial designLongitudinal structural MRIMagnetic resonance imagingSingle photon emissionDevelopment of treatmentsDiffusion tensor imagingBiomarker predictorsPlaque pathologyAmyloid pathologyDopamine deficiencyDopaminergic deficitUnivariate analysisBiomarker changesDisorders CenterHyperinsulinemia and elevated systolic blood pressure independently predict white matter hyperintensities with associated cognitive decrement in the middle-aged offspring of dementia patients
Hawkins KA, Emadi N, Pearlson GD, Winkler AM, Taylor B, Dulipsingh L, King D, Pittman B, Blank K. Hyperinsulinemia and elevated systolic blood pressure independently predict white matter hyperintensities with associated cognitive decrement in the middle-aged offspring of dementia patients. Metabolic Brain Disease 2017, 32: 849-857. PMID: 28255864, DOI: 10.1007/s11011-017-9980-9.Peer-Reviewed Original ResearchConceptsSystolic blood pressureWMH volumeVascular riskBlood pressurePlasma insulinDementia patientsMRI white matter hyperintensity volumeCognitive declineElevated systolic blood pressureSmall dense LDL-cholesterolWhite matter hyperintensity volumeH systolic BPIndependent risk factorDense LDL cholesterolCognitive decrementsBody mass indexWhite matter damageWhite matter hyperintensitiesApoE ε4 effectMiddle-aged offspringCerebral infarctsLifestyle modificationAggressive treatmentCerebrovascular damageLDL cholesterol
2015
Cognitive and functional status predictors of delirium and delirium severity after coronary artery bypass graft surgery: an interim analysis of the Neuropsychiatric Outcomes After Heart Surgery study
Oldham MA, Hawkins KA, Yuh DD, Dewar ML, Darr UM, Lysyy T, Lee HB. Cognitive and functional status predictors of delirium and delirium severity after coronary artery bypass graft surgery: an interim analysis of the Neuropsychiatric Outcomes After Heart Surgery study. International Psychogeriatrics 2015, 27: 1929-1938. PMID: 26423721, PMCID: PMC9310349, DOI: 10.1017/s1041610215001477.Peer-Reviewed Original ResearchConceptsMild cognitive impairmentHeart Surgery studyConfusion Assessment MethodPost-operative deliriumDelirium severityLawton IADL scoresIADL scoresNeuropsychiatric outcomesDelirium IndexSurgery StudyCoronary artery bypass graft surgeryArtery bypass graft surgeryPost-operative day 2Clinical Dementia Rating ScaleMCI-NCElective CABG surgeryBypass graft surgeryObservational cohort studyDementia Rating ScaleCABG surgeryGraft surgeryCohort studyFunctional statusFunctional impairmentCDR sumCognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease
Weintraub D, Simuni T, Caspell‐Garcia C, Coffey C, Lasch S, Siderowf A, Aarsland D, Barone P, Burn D, Chahine M, Eberling J, Espay AJ, Foster ED, Leverenz JB, Litvan I, Richard I, Troyer MD, Hawkins KA, Initiative T. Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. Movement Disorders 2015, 30: 919-927. PMID: 25737166, PMCID: PMC4855523, DOI: 10.1002/mds.26170.Peer-Reviewed Original ResearchConceptsParkinson's Progression Markers InitiativeNeuropsychiatric symptomsPD patientsHealthy controlsProgression Markers InitiativeParkinson's diseaseCognitive impairmentUntreated PD patientsDopamine replacement therapySignificant depressive symptomsGroup differencesSymptoms of depressionQuality of lifeMild cognitive impairmentUntreated patientsDisease courseReplacement therapyICD symptomsControl disordersDepressive symptomsGeneral populationPatientsMeeting criteriaMulti-site studyBiological predictors